ENTITY
Shanghai Junshi Biosciences

Shanghai Junshi Biosciences (1877 HK)

229
Analysis
Health CareChina
Shanghai Junshi Biosciences Co., Ltd. operates as a biopharmaceutical company. The Company develops and sells small molecule drugs, antibody drug conjugates, and other products. Shanghai Junshi Biosciences markets its products worldwide.
more
16 Jan 2025 15:02

Shanghai Junshi Bioscience (1877 HK): Key Drug on High Trajectory; Geopolitical Tension Spoils Party

​Shanghai Junshi Biosciences sees strong revenue growth for toripalimab in China. While US launch of the drug was in-line, geopolitical tensions...

Logo
393 Views
Share
13 Apr 2023 01:12

[Junshi Biosciences (1877 HK) TP Change]: Medium to near Term Outlook Is Still Cloudy at Best

We continue to view JUNSHI’s Phase III pipeline, consisting of Senaparib (JS109/IMP4297)(PARP), Ongericimab (JS002)(PCSK9), Bevacizumab...

Share
07 Jul 2024 01:19

China Healthcare Weekly (July.7) - MNCs' Next Move In Licensing Deals, Topchoice, Junshi's Trouble

​Investors should wait to see MNCs' next move before deciding on licensing deals. Topchoice's growth is positive but unit price per customer may...

Logo
458 Views
Share
03 Apr 2022 23:57

Innovent Biologics Inc (1801.HK) - Capable of Surviving “this Winter”

After continuous pullback, investors may lose interest in Innovent. However, it still has investment value based on pipeline, resources, R&D and...

Logo
338 Views
Share
26 Jan 2025 00:30

APAC Healthcare Weekly (Jan 26)- Daiichi Sankyo, Sumitomo Pharma, Fosun Pharma, SK Bioscience, Hugel

APAC healthcare companies got approvals for new products as well as clinical trials. The companies continued with acquisitions and collaborations...

Logo
379 Views
Share
x